There has been one study on the Joint Hypermobility Syndrome at the ACR 2015 Annual Meeting in San Francisco, abbreviated by the authors: JHS. Jesus, I hope the pope won’t read this as JHS is called the christogramm, derived of the name Jesus (in Greek: ΙΗΣ). Back to the topic. I like more to call the syndrome the benign joint hypermobility syndrome to make sure, we aren’t talking about Ehlers-Danlos syndrome, whereof there were two studies at the ACR 2015 Annual Meeting. Let’s have a closer look at the study.
Anand Patel and colleagues presented: “Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome”. Conclusion: “This is the first study examining MVP in patients with JHS using the updated MVP ECHO criteria. We did not find ECHO findings consistent with MVP in our JHS patients. […]”.
Please don’t stone me. I’ve never done routine echocardiography on my joint hypermobility syndrome patients, maybe, because I call the syndrome benign and don’t expect mitral valve prolaps in this group of hypermobility patients. I would act differently in patients with Ehlers-Danlos or Marfan’s syndrome. But for those, who did routine echocardiography before, this study offers enough reason to save time and money. The authors are a bit overcautious and warrant a study in other rheumatology practices. D’accord!
Patel A, Schwartz M, Cohen L, Shindler D, Moreyra A, Schlesinger N. Mitral Valve Prolapse in Patients with Joint Hypermobility Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). http://acrabstracts.org/abstract/mitral-valve-prolapse-in-patients-with-joint-hypermobility-syndrome/. Accessed December 1, 2015.